50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Poseida reports positive interim data on CAR-T therapies

Published 12/09/2024, 12:05 PM
PSTX
-

SAN DIEGO - Poseida Therapeutics, Inc. (NASDAQ: PSTX), a biopharmaceutical company with a market capitalization of $916 million and impressive year-to-date returns of 178%, has presented interim clinical data from its Phase 1 trial of P-BCMA-ALLO1, a therapy for relapsed/refractory multiple myeloma (RRMM), at the 66th ASH Annual Meeting and Exposition. According to InvestingPro analysis, the company's stock is trading near its 52-week high, reflecting strong investor confidence in its clinical developments. The data includes new profiling of patient responses from an optimized lymphodepletion arm, demonstrating consistent cellular expansion and persistence of the therapy across different subgroups.

The P-BCMA-ALLO1 therapy, which is being developed in collaboration with Roche, has shown a 91% overall response rate (ORR) in the optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients. The treatment also exhibited a differentiated safety profile with no dose-limiting toxicities and low rates of common side effects, all Grade 2 or less. This development comes as Poseida demonstrates strong revenue growth of 203% in the last twelve months, though InvestingPro data indicates the company maintains a focus on research and development with current negative profit margins.

In addition to P-BCMA-ALLO1, Poseida introduced preclinical data for P-CD19CD20-ALLO1, its first dual CAR-T therapy targeting B-cell malignancies. The preclinical results suggest higher and more durable tumor cell killing compared to single-target CAR-T cells, with increased cytotoxicity and sustained effector cytokine levels.

A case study was also presented, showcasing the reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in a patient with relapsed multiple myeloma. The patient achieved and maintained a stringent complete response over 12 months post reactivation, indicating the potential of TSCM-based CAR-T therapies for long-term remission.

P-BCMA-ALLO1 has been granted Orphan Drug and Regenerative Medicine Advanced Therapy designations by the FDA for multiple myeloma. The Phase 1/1b trial is ongoing, with more information available on clinicaltrials.gov (NCT04960579). P-CD19CD20-ALLO1 is also in a Phase 1 study for B-cell malignancies (NCT06014762), with initial clinical data expected in 2025.

This news is based on a press release statement and reflects interim data that may change as more patient data become available. Poseida Therapeutics continues to explore the efficacy and safety of its CAR-T therapies in clinical trials. The company maintains a strong financial position with a current ratio of 3.2, indicating solid liquidity to support its ongoing research initiatives. For deeper insights into Poseida's financial health and growth prospects, investors can access comprehensive analysis and 16 additional ProTips through InvestingPro's detailed research reports.

In other recent news, Poseida Therapeutics has seen considerable developments. The company's acquisition by Roche, in a deal potentially worth up to $1.5 billion, is set to bolster Roche's portfolio in the area of cell therapies. Financially, Poseida is estimated to have pro forma cash reserves of approximately $246 million, with an outstanding debt of $58.9 million. However, the acquisition has led to a downgrade in Poseida's valuation, reflecting the terms set by Roche.

Poseida has also been making significant strides in the development of CAR-T cell therapies. The company recently presented promising results from a study evaluating P-BCMA-ALLO1 for the treatment of relapsed and refractory multiple myeloma, showing a 91% overall response rate. Furthermore, Poseida has nominated a new CAR-T therapy development candidate, triggering a $15 million milestone payment as part of their collaboration with Roche.

Analysts from firms such as Piper Sandler and H.C. Wainwright have maintained positive ratings on Poseida, with H.C. Wainwright reiterating a Buy rating and a $20.00 stock price target. These recent developments highlight the ongoing progress and collaborations in Poseida Therapeutics' mission to advance allogeneic cell therapies and genetic medicines.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.